JP2016164184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016164184A5 JP2016164184A5 JP2016081792A JP2016081792A JP2016164184A5 JP 2016164184 A5 JP2016164184 A5 JP 2016164184A5 JP 2016081792 A JP2016081792 A JP 2016081792A JP 2016081792 A JP2016081792 A JP 2016081792A JP 2016164184 A5 JP2016164184 A5 JP 2016164184A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pyridin
- triazolo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 150000002431 hydrogen Chemical class 0.000 claims 29
- -1 nitro, hydroxy Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 19
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 4
- 150000002357 guanidines Chemical class 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical group COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ORMPCQCCZCCYRS-UHFFFAOYSA-N 1-pyrrolidin-1-yl-2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]pyrazol-1-yl]ethanone Chemical compound C1=C(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)C=NN1CC(=O)N1CCCC1 ORMPCQCCZCCYRS-UHFFFAOYSA-N 0.000 claims 1
- ALWGIHOBLHQXHI-UHFFFAOYSA-N 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 ALWGIHOBLHQXHI-UHFFFAOYSA-N 0.000 claims 1
- GPIHCFYCDZFCDV-UHFFFAOYSA-N 2-[4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 GPIHCFYCDZFCDV-UHFFFAOYSA-N 0.000 claims 1
- UWAXBTWQEMCYOB-UHFFFAOYSA-N 2-[4-[3-[(4-fluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CC=C(N=NN2CC=3C=CC(F)=CC=3)C2=N1 UWAXBTWQEMCYOB-UHFFFAOYSA-N 0.000 claims 1
- LJPOWVUYWNNDPJ-UHFFFAOYSA-N 2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 LJPOWVUYWNNDPJ-UHFFFAOYSA-N 0.000 claims 1
- UYAQGFXNQDLVJN-UHFFFAOYSA-N 2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 UYAQGFXNQDLVJN-UHFFFAOYSA-N 0.000 claims 1
- HITBWJDLEMFHPX-UHFFFAOYSA-N 2-fluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 HITBWJDLEMFHPX-UHFFFAOYSA-N 0.000 claims 1
- MNNQPYIMWLYJPE-UHFFFAOYSA-N 2-fluoro-5-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 MNNQPYIMWLYJPE-UHFFFAOYSA-N 0.000 claims 1
- XLJAEALBDQMDPH-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methyl]-5-(1h-pyrazol-4-yl)triazolo[4,5-b]pyridine Chemical compound FC1=CC=C(F)C(CN2C3=NC(=CC=C3N=N2)C2=CNN=C2)=C1Cl XLJAEALBDQMDPH-UHFFFAOYSA-N 0.000 claims 1
- RHGWLAMTNFNTTC-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-(1h-pyrazol-4-yl)triazolo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1CN1C2=NC(C3=CNN=C3)=CC=C2N=N1 RHGWLAMTNFNTTC-UHFFFAOYSA-N 0.000 claims 1
- VYQMYFVPYBLEMZ-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[1-[2-(oxan-2-yloxy)ethyl]pyrazol-4-yl]triazolo[4,5-b]pyridine Chemical compound C1=CC(F)=CC=C1CN1C2=NC(C3=CN(CCOC4OCCCC4)N=C3)=CC=C2N=N1 VYQMYFVPYBLEMZ-UHFFFAOYSA-N 0.000 claims 1
- VDAHJTPNAURLGG-UHFFFAOYSA-N 3-[2-fluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]anilino]propanoic acid Chemical compound C1=C(F)C(NCCC(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 VDAHJTPNAURLGG-UHFFFAOYSA-N 0.000 claims 1
- UFXQSELVQCEGNG-UHFFFAOYSA-N 3-[2-fluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenoxy]-n,n-dimethylpropan-1-amine Chemical compound C1=C(F)C(OCCCN(C)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 UFXQSELVQCEGNG-UHFFFAOYSA-N 0.000 claims 1
- QLQUQUKKUXUUTL-UHFFFAOYSA-N 3-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenol Chemical compound OC1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 QLQUQUKKUXUUTL-UHFFFAOYSA-N 0.000 claims 1
- HWWJLBMAILCFQO-UHFFFAOYSA-N 4-[2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]pyrazol-1-yl]ethyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)C=NN1CCN1CCOCC1 HWWJLBMAILCFQO-UHFFFAOYSA-N 0.000 claims 1
- NWLGQZOICWXIDQ-UHFFFAOYSA-N 4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 NWLGQZOICWXIDQ-UHFFFAOYSA-N 0.000 claims 1
- WZOOINDUBKOYLP-UHFFFAOYSA-N 4-[3-[(2-chloro-3,6-difluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]-2-fluoro-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=CC=C(N=NN2CC=3C(=C(F)C=CC=3F)Cl)C2=N1 WZOOINDUBKOYLP-UHFFFAOYSA-N 0.000 claims 1
- QNLWFZHIVAIMIX-UHFFFAOYSA-N 4-[3-[(2-chloro-3,6-difluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C(=C(F)C=CC=3F)Cl)C2=N1 QNLWFZHIVAIMIX-UHFFFAOYSA-N 0.000 claims 1
- RAFIMVFKDKTGCA-UHFFFAOYSA-N 4-[5-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]pyridin-2-yl]morpholine Chemical compound C=1C=C2N=CC=CC2=CC=1CN(C1=N2)N=NC1=CC=C2C(C=N1)=CC=C1N1CCOCC1 RAFIMVFKDKTGCA-UHFFFAOYSA-N 0.000 claims 1
- HWXVFQMRTFVHNM-UHFFFAOYSA-N 5-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 HWXVFQMRTFVHNM-UHFFFAOYSA-N 0.000 claims 1
- BKKFMXBUPHSOLH-UHFFFAOYSA-N 6-[(5-pyridin-3-yltriazolo[4,5-b]pyridin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1CN(C1=N2)N=NC1=CC=C2C1=CC=CN=C1 BKKFMXBUPHSOLH-UHFFFAOYSA-N 0.000 claims 1
- FHZXWTLERUQXSJ-UHFFFAOYSA-N 6-[1-[5-(1h-pyrazol-4-yl)triazolo[4,5-b]pyridin-3-yl]ethyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(C)N(C1=N2)N=NC1=CC=C2C=1C=NNC=1 FHZXWTLERUQXSJ-UHFFFAOYSA-N 0.000 claims 1
- PZTDNJQKFWDRCA-UHFFFAOYSA-N 6-[2-[5-(1h-pyrazol-4-yl)triazolo[4,5-b]pyridin-3-yl]propan-2-yl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(C)(C)N(C1=N2)N=NC1=CC=C2C=1C=NNC=1 PZTDNJQKFWDRCA-UHFFFAOYSA-N 0.000 claims 1
- YAHRBSLCKASTSJ-UHFFFAOYSA-N 6-[[5-(1,3-benzodioxol-5-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C2OCOC2=CC(C2=CC=C3N=NN(C3=N2)CC=2C=C3C=CC=NC3=CC=2)=C1 YAHRBSLCKASTSJ-UHFFFAOYSA-N 0.000 claims 1
- CSXOGDAIIWKSQA-UHFFFAOYSA-N 6-[[5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 CSXOGDAIIWKSQA-UHFFFAOYSA-N 0.000 claims 1
- SZHOGKOEYCYZDY-UHFFFAOYSA-N 6-[[5-(1-propan-2-ylpyrazol-4-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=NN(C(C)C)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 SZHOGKOEYCYZDY-UHFFFAOYSA-N 0.000 claims 1
- SJBXSAIMLUFQDU-UHFFFAOYSA-N 6-[[5-(2,3-dihydro-1-benzofuran-5-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C2OCCC2=CC(C2=CC=C3N=NN(C3=N2)CC=2C=C3C=CC=NC3=CC=2)=C1 SJBXSAIMLUFQDU-UHFFFAOYSA-N 0.000 claims 1
- QZKXDQKEKSAKKF-UHFFFAOYSA-N 6-[[5-(2-chloropyridin-4-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=NC(Cl)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 QZKXDQKEKSAKKF-UHFFFAOYSA-N 0.000 claims 1
- HRIPFUDSGLOHJK-UHFFFAOYSA-N 6-[[5-(2-methoxypyrimidin-5-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=NC(OC)=NC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 HRIPFUDSGLOHJK-UHFFFAOYSA-N 0.000 claims 1
- YHGDKKUDPGIYAX-UHFFFAOYSA-N 6-[[5-(3-ethyl-2h-indazol-6-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C=3C=C4NN=C(C4=CC=3)CC)=CC=C21 YHGDKKUDPGIYAX-UHFFFAOYSA-N 0.000 claims 1
- NZXKWYYKGUFLDC-UHFFFAOYSA-N 6-[[5-(3-fluoro-4-methoxyphenyl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(F)C(OC)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 NZXKWYYKGUFLDC-UHFFFAOYSA-N 0.000 claims 1
- UNDZNEMPJSSXBA-UHFFFAOYSA-N 6-[[5-(3-fluoro-4-propan-2-yloxyphenyl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(F)C(OC(C)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 UNDZNEMPJSSXBA-UHFFFAOYSA-N 0.000 claims 1
- BPBRABRIFQMQNN-UHFFFAOYSA-N 6-[[5-(3-methyl-2h-indazol-5-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C3=CC=C4NN=C(C4=C3)C)=CC=C21 BPBRABRIFQMQNN-UHFFFAOYSA-N 0.000 claims 1
- WZWLRCQHBFCPMJ-UHFFFAOYSA-N 6-[[5-(4-methylpiperazin-1-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1CN(C)CCN1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 WZWLRCQHBFCPMJ-UHFFFAOYSA-N 0.000 claims 1
- PYDGAVYKYVRRBU-UHFFFAOYSA-N 6-[[5-(4-methylthiophen-2-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound CC1=CSC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 PYDGAVYKYVRRBU-UHFFFAOYSA-N 0.000 claims 1
- KVUBAQLZTUEXJY-UHFFFAOYSA-N 6-[[5-(5-methyl-1h-pyrazol-4-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound CC1=NNC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 KVUBAQLZTUEXJY-UHFFFAOYSA-N 0.000 claims 1
- QALNKKMNDHKQFK-UHFFFAOYSA-N 6-[[5-(5-methylthiophen-2-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound S1C(C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 QALNKKMNDHKQFK-UHFFFAOYSA-N 0.000 claims 1
- DYEJAVYGLJOIMC-UHFFFAOYSA-N 6-[[5-(6-piperidin-1-ylpyridin-3-yl)triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1CN(C1=N2)N=NC1=CC=C2C(C=N1)=CC=C1N1CCCCC1 DYEJAVYGLJOIMC-UHFFFAOYSA-N 0.000 claims 1
- IGIUTMDUBFGCAM-UHFFFAOYSA-N 6-[[5-[1-(2-fluoroethyl)pyrazol-4-yl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=NN(CCF)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 IGIUTMDUBFGCAM-UHFFFAOYSA-N 0.000 claims 1
- VCFLTCNSYFRNTD-SFHVURJKSA-N 6-[[5-[1-[(3s)-pyrrolidin-3-yl]pyrazol-4-yl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1CN(C1=N2)N=NC1=CC=C2C(=C1)C=NN1[C@H]1CCNC1 VCFLTCNSYFRNTD-SFHVURJKSA-N 0.000 claims 1
- KAHHADLNMIZCIU-FERBBOLQSA-N 6-[[5-[1-[(3s)-pyrrolidin-3-yl]pyrazol-4-yl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline;hydrochloride Chemical compound Cl.C=1C=C2N=CC=CC2=CC=1CN(C1=N2)N=NC1=CC=C2C(=C1)C=NN1[C@H]1CCNC1 KAHHADLNMIZCIU-FERBBOLQSA-N 0.000 claims 1
- WYHMGKKHEXQPLZ-UHFFFAOYSA-N 6-[[5-[1-[2-(oxan-2-yloxy)ethyl]pyrazol-4-yl]imidazo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)C=NC3=CC=2)C=NN1CCOC1CCCCO1 WYHMGKKHEXQPLZ-UHFFFAOYSA-N 0.000 claims 1
- SYRZXJREPPVSLQ-UHFFFAOYSA-N 6-[[5-[1-[2-(oxan-2-yloxy)ethyl]pyrazol-4-yl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)C=NN1CCOC1CCCCO1 SYRZXJREPPVSLQ-UHFFFAOYSA-N 0.000 claims 1
- MGVOQNWFIKYNRQ-UHFFFAOYSA-N 6-[[5-[3-(2,2,2-trifluoroethoxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound FC(F)(F)COC1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 MGVOQNWFIKYNRQ-UHFFFAOYSA-N 0.000 claims 1
- KDLQLIDBKPAYPG-UHFFFAOYSA-N 6-[[5-[3-(difluoromethoxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound FC(F)OC1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 KDLQLIDBKPAYPG-UHFFFAOYSA-N 0.000 claims 1
- KFCJESDVMBISFX-UHFFFAOYSA-N 6-[[5-[3-(trifluoromethoxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound FC(F)(F)OC1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 KFCJESDVMBISFX-UHFFFAOYSA-N 0.000 claims 1
- LJDJZKISZSVCNZ-UHFFFAOYSA-N 6-[[5-[3-fluoro-4-(2-methoxyethoxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(F)C(OCCOC)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 LJDJZKISZSVCNZ-UHFFFAOYSA-N 0.000 claims 1
- FNZWPWVGNLXRLO-UHFFFAOYSA-N 6-[[5-[3-fluoro-4-(2-methylpropoxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound C1=C(F)C(OCC(C)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 FNZWPWVGNLXRLO-UHFFFAOYSA-N 0.000 claims 1
- SDZUYTJIZLNDPN-UHFFFAOYSA-N 6-[[5-[3-fluoro-4-(oxan-4-yloxy)phenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound FC1=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=CC=C1OC1CCOCC1 SDZUYTJIZLNDPN-UHFFFAOYSA-N 0.000 claims 1
- SAXRTVKOLWFSFL-UHFFFAOYSA-N 6-[[5-[4-(cyclopropylmethoxy)-3-fluorophenyl]triazolo[4,5-b]pyridin-3-yl]methyl]quinoline Chemical compound FC1=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=CC=C1OCC1CC1 SAXRTVKOLWFSFL-UHFFFAOYSA-N 0.000 claims 1
- RKUJPBFUCQBRTP-UHFFFAOYSA-N C1(=CC=CC=C1)NC1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2.N2=CC=CC1=CC(=CC=C21)CN2N=NC=1C2=NC(=CC1)NCCO Chemical compound C1(=CC=CC=C1)NC1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2.N2=CC=CC1=CC(=CC=C21)CN2N=NC=1C2=NC(=CC1)NCCO RKUJPBFUCQBRTP-UHFFFAOYSA-N 0.000 claims 1
- HUPIYYWGUNFYQA-UHFFFAOYSA-N COC(C=CC(C1=CC=C2N=NN(CC(C=C3C=C4)=CC=C3N=C4NC(C=C3)=CC=C3C3=CC=C4N=NN(CC5=CC=C6N=CC=CC6=C5)C4=N3)C2=N1)=C1)=C1OC Chemical compound COC(C=CC(C1=CC=C2N=NN(CC(C=C3C=C4)=CC=C3N=C4NC(C=C3)=CC=C3C3=CC=C4N=NN(CC5=CC=C6N=CC=CC6=C5)C4=N3)C2=N1)=C1)=C1OC HUPIYYWGUNFYQA-UHFFFAOYSA-N 0.000 claims 1
- HJBFOVDCEJKURK-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)C(C)(C)N1N=NC=2C1=NC(=CC2)C=2C=NN(C2)CCO.N2=CC=CC1=CC=CC=C21 Chemical compound N1=CC=CC2=CC(=CC=C12)C(C)(C)N1N=NC=2C1=NC(=CC2)C=2C=NN(C2)CCO.N2=CC=CC1=CC=CC=C21 HJBFOVDCEJKURK-UHFFFAOYSA-N 0.000 claims 1
- PTQCZUCQIIDTLH-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)CN1N=NC=2C1=NC(=CC2)C(C)=O.O(C2=CC=CC=C2)C2=CC=C1C(=N2)N(N=N1)CC=1C=C2C=CC=NC2=CC1 Chemical compound N1=CC=CC2=CC(=CC=C12)CN1N=NC=2C1=NC(=CC2)C(C)=O.O(C2=CC=CC=C2)C2=CC=C1C(=N2)N(N=N1)CC=1C=C2C=CC=NC2=CC1 PTQCZUCQIIDTLH-UHFFFAOYSA-N 0.000 claims 1
- GSJADQZCDDDYJK-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)CN1N=NC=2C1=NC(=CC2)C2=CC=C(C=O)C=C2.N2=CC=CC1=CC(=CC=C21)CN2N=NC=1C2=NC(=CC1)C=1C=C(C=O)C=CC1 Chemical compound N1=CC=CC2=CC(=CC=C12)CN1N=NC=2C1=NC(=CC2)C2=CC=C(C=O)C=C2.N2=CC=CC1=CC(=CC=C21)CN2N=NC=1C2=NC(=CC1)C=1C=C(C=O)C=CC1 GSJADQZCDDDYJK-UHFFFAOYSA-N 0.000 claims 1
- GTLUBJXAXRRVMG-UHFFFAOYSA-N N1C=CC2=CC=C(C=C12)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2.N2C=CC1=CC(=CC=C21)C2=CC=C1C(=N2)N(N=N1)CC=1C=C2C=CC=NC2=CC1 Chemical compound N1C=CC2=CC=C(C=C12)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2.N2C=CC1=CC(=CC=C21)C2=CC=C1C(=N2)N(N=N1)CC=1C=C2C=CC=NC2=CC1 GTLUBJXAXRRVMG-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KMBSLDHUDPDCBQ-UHFFFAOYSA-N [1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]urea Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C(=NNC(N)=O)C)=CC=C21 KMBSLDHUDPDCBQ-UHFFFAOYSA-N 0.000 claims 1
- MZFIFYQYUZGDPI-UHFFFAOYSA-N [4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]thiophen-2-yl]methanol Chemical compound S1C(CO)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 MZFIFYQYUZGDPI-UHFFFAOYSA-N 0.000 claims 1
- MURJOSYVAGPAQD-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CC=C(N=NN2CC=3C=CC(F)=CC=3)C2=N1 MURJOSYVAGPAQD-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- KSSLZZVHAGGQFQ-UHFFFAOYSA-N methyl 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(F)C(C(=O)OC)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 KSSLZZVHAGGQFQ-UHFFFAOYSA-N 0.000 claims 1
- RSBOXYMVOHVEMI-UHFFFAOYSA-N methyl 2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(Cl)C(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 RSBOXYMVOHVEMI-UHFFFAOYSA-N 0.000 claims 1
- MKHLTJXMPGNSKU-UHFFFAOYSA-N methyl 2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(Cl)C(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 MKHLTJXMPGNSKU-UHFFFAOYSA-N 0.000 claims 1
- XXNRZVVXHYGCPH-UHFFFAOYSA-N methyl 2-fluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(F)C(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 XXNRZVVXHYGCPH-UHFFFAOYSA-N 0.000 claims 1
- QINQZHIEGPUZBW-UHFFFAOYSA-N methyl 2-fluoro-5-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(F)C(C(=O)OC)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 QINQZHIEGPUZBW-UHFFFAOYSA-N 0.000 claims 1
- IZVPOZNJDPRWCL-UHFFFAOYSA-N methyl 3-[2-fluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]anilino]propanoate Chemical compound C1=C(F)C(NCCC(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 IZVPOZNJDPRWCL-UHFFFAOYSA-N 0.000 claims 1
- PBZOJLDUWZQLIV-UHFFFAOYSA-N methyl 3-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 PBZOJLDUWZQLIV-UHFFFAOYSA-N 0.000 claims 1
- FGVXKWQRBSXXSX-UHFFFAOYSA-N methyl 4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 FGVXKWQRBSXXSX-UHFFFAOYSA-N 0.000 claims 1
- HFDSLIGWNYUQCZ-UHFFFAOYSA-N methyl 4-[3-[(2-chloro-3,6-difluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]-2-fluorobenzoate Chemical compound C1=C(F)C(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C(=C(F)C=CC=3F)Cl)C2=N1 HFDSLIGWNYUQCZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- VRWGLCYXMBLWHN-UHFFFAOYSA-N n-[1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]acetamide Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C(C)=NNC(=O)C)=CC=C21 VRWGLCYXMBLWHN-UHFFFAOYSA-N 0.000 claims 1
- ZUEJGCCADGGVFR-UHFFFAOYSA-N n-[1-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]ethylideneamino]pyridine-4-carboxamide Chemical compound C=1C=C2N=NN(CC=3C=C4C=CC=NC4=CC=3)C2=NC=1C(C)=NNC(=O)C1=CC=NC=C1 ZUEJGCCADGGVFR-UHFFFAOYSA-N 0.000 claims 1
- UVPUOLXMNDESPM-UHFFFAOYSA-N n-[3-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 UVPUOLXMNDESPM-UHFFFAOYSA-N 0.000 claims 1
- UDZWLEIFSUEXEW-UHFFFAOYSA-N n-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 UDZWLEIFSUEXEW-UHFFFAOYSA-N 0.000 claims 1
- XSCNIMXHISBTPW-UHFFFAOYSA-N n-propan-2-yl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC(C)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 XSCNIMXHISBTPW-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- BPKZMLAITURJBG-UHFFFAOYSA-N tert-butyl 3-ethyl-6-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]indazole-1-carboxylate Chemical compound N1=CC=CC2=CC(CN3N=NC4=CC=C(N=C43)C=3C=C4N(C(=O)OC(C)(C)C)N=C(C4=CC=3)CC)=CC=C21 BPKZMLAITURJBG-UHFFFAOYSA-N 0.000 claims 1
- ZPCUSVRPYLKXHE-UHFFFAOYSA-N tert-butyl 4-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 ZPCUSVRPYLKXHE-UHFFFAOYSA-N 0.000 claims 1
- CZWFKGHNFYZUGX-UHFFFAOYSA-N tert-butyl 4-[4-[3-[(2-chloro-3,6-difluorophenyl)methyl]triazolo[4,5-b]pyridin-5-yl]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(C=2N=C3N(CC=4C(=C(F)C=CC=4F)Cl)N=NC3=CC=2)=C1 CZWFKGHNFYZUGX-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1377CH2010 | 2010-05-17 | ||
| IN1377/CHE/2010 | 2010-05-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510708A Division JP5960688B2 (ja) | 2010-05-17 | 2011-05-13 | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016164184A JP2016164184A (ja) | 2016-09-08 |
| JP2016164184A5 true JP2016164184A5 (cg-RX-API-DMAC10.html) | 2016-11-10 |
| JP6286472B2 JP6286472B2 (ja) | 2018-02-28 |
Family
ID=44315015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510708A Expired - Fee Related JP5960688B2 (ja) | 2010-05-17 | 2011-05-13 | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| JP2016081792A Expired - Fee Related JP6286472B2 (ja) | 2010-05-17 | 2016-04-15 | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510708A Expired - Fee Related JP5960688B2 (ja) | 2010-05-17 | 2011-05-13 | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8481739B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3450432A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5960688B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR101871436B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN107674073B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2011254242B2 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2798080C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2571878T3 (cg-RX-API-DMAC10.html) |
| EA (2) | EA025281B9 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2715611T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL222977A (cg-RX-API-DMAC10.html) |
| NZ (2) | NZ604306A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011145035A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025466B1 (ru) | 2009-12-31 | 2016-12-30 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| NZ604306A (en) * | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| US9815831B2 (en) * | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| AU2015204210B2 (en) * | 2014-01-06 | 2019-07-18 | Rhizen Pharmaceuticals Sa | Inhibitors of glutaminase |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
| EP3236968A4 (en) * | 2014-12-23 | 2018-08-01 | Pharmacyclics LLC | Btk inhibitor combinations and dosing regimen |
| EP3268358A1 (en) | 2015-03-13 | 2018-01-17 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| WO2016208744A1 (ja) | 2015-06-25 | 2016-12-29 | 大鵬薬品工業株式会社 | 線維症治療剤 |
| MY186368A (en) * | 2015-07-20 | 2021-07-16 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| US9782370B2 (en) | 2015-12-21 | 2017-10-10 | Gongwin Biopharm Holdings Co., Ltd. | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma |
| AU2017247798C1 (en) * | 2016-04-07 | 2020-08-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| PT3458443T (pt) | 2016-05-03 | 2020-11-05 | Bayer Pharma AG | Derivados de sulfonamida aromática |
| CA3053739C (en) | 2017-02-15 | 2023-02-14 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| WO2018210729A1 (en) | 2017-05-18 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| AU2018356430A1 (en) | 2017-10-29 | 2020-04-30 | Bayer Aktiengesellschaft | Aromatic sulfonamide derivatives for the treatment of Ischemic Stroke |
| CN110294751B (zh) * | 2018-03-21 | 2020-11-20 | 湖南化工研究院有限公司 | 具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用 |
| CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| CN111116585B (zh) * | 2019-12-31 | 2021-02-05 | 北京鑫开元医药科技有限公司 | 具有c-MET激酶抑制活性化合物、制备方法、组合物及用途 |
| EP4146639A1 (en) | 2020-05-06 | 2023-03-15 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| CN118834216A (zh) * | 2022-07-15 | 2024-10-25 | 北京达尔文细胞生物科技有限公司 | 一种式ⅰ化合物的制备方法及其用于应激诱导细胞的应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| FR2527608B1 (fr) * | 1982-05-28 | 1986-10-10 | Sandoz Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments |
| BE896797A (fr) * | 1982-05-28 | 1983-11-21 | Sandoz Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments. |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0470543A1 (de) | 1990-08-10 | 1992-02-12 | Dr. Karl Thomae GmbH | Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| BR9710381A (pt) | 1996-07-18 | 1999-08-17 | Pfizer | Inibidores de metaloproteases de matriz - base de fosfinato |
| CN1228083A (zh) | 1996-08-23 | 1999-09-08 | 美国辉瑞有限公司 | 芳基磺酰氨基异羟肟酸衍生物 |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| ATE254615T1 (de) | 1999-02-22 | 2003-12-15 | Biotechnolog Forschung Gmbh | C-21 modifizierte epothilone |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| WO2005007891A2 (en) | 2003-06-19 | 2005-01-27 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Variants of human taste receptor genes |
| MXPA06000091A (es) * | 2003-07-02 | 2006-04-07 | Sugen Inc | Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met. |
| US20050101650A1 (en) | 2003-08-15 | 2005-05-12 | Alex Aronov | Pyrrole compositions useful as inhibitors of c-Met |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| CA2539726A1 (en) | 2003-09-24 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AU2005270068B2 (en) | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| EP1786777A1 (en) | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| ATE492544T1 (de) | 2004-08-26 | 2011-01-15 | Pfizer | Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer |
| CA2578066C (en) | 2004-08-26 | 2011-10-11 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| US7528138B2 (en) | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| US7470693B2 (en) | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ES2441178T3 (es) * | 2005-06-01 | 2014-02-03 | Ucb Pharma, S.A. | Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| DE602007004092D1 (de) | 2006-03-22 | 2010-02-11 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| EP2057164A1 (en) * | 2006-08-07 | 2009-05-13 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| CN101796056A (zh) | 2006-09-18 | 2010-08-04 | 沃泰克斯药物股份有限公司 | c-MET的杂环抑制剂及其用途 |
| MX2009004060A (es) | 2006-10-23 | 2009-06-19 | Sgx Pharmaceuticals Inc | Moduladores de proteina cinasa de triazolpiridazina. |
| KR20090075873A (ko) | 2006-10-31 | 2009-07-09 | 쉐링 코포레이션 | 아닐리노피페라진 유도체 및 이의 사용방법 |
| WO2008060866A1 (en) | 2006-11-14 | 2008-05-22 | Smithkline Beecham Corporation | Novel compounds |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| EP3443958A1 (en) * | 2006-11-22 | 2019-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| WO2008078085A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Method |
| ES2531002T3 (es) | 2007-01-19 | 2015-03-09 | Xcovery Inc | Compuestos inhibidores de quinasa |
| AU2008217931A1 (en) | 2007-02-23 | 2008-08-28 | Eisai R & D Management Co., Ltd. | Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene |
| FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| FR2915199B1 (fr) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
| CA2690799C (en) | 2007-06-22 | 2015-06-16 | Arqule, Inc. | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
| WO2009014012A1 (ja) | 2007-07-25 | 2009-01-29 | Kyouwagiken Co., Ltd. | ボール回転調節装置、発射装置用アタッチメント、ボール発射装置 |
| CA2703979A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Heterocyclic ether and thioether derivatives and methods of use thereof |
| MX2010004876A (es) | 2007-10-29 | 2010-07-28 | Schering Corp | Derivados de diamido tiazol como inhibidores de la proteina cinasa. |
| JP2011502160A (ja) | 2007-10-29 | 2011-01-20 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としての複素環式尿素およびチオ尿素誘導体ならびにそれらの使用方法 |
| CN101910165A (zh) | 2007-10-29 | 2010-12-08 | 先灵公司 | 作为蛋白质激酶抑制剂的噻唑衍生物 |
| CA2717509A1 (en) * | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| BRPI0912668A2 (pt) * | 2008-05-13 | 2016-01-26 | Irm Llc | composto e composições como inibidores de quinase |
| EP2298731A4 (en) * | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| KR20120089643A (ko) * | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
| IN2012DN01453A (cg-RX-API-DMAC10.html) * | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| EA025466B1 (ru) * | 2009-12-31 | 2016-12-30 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| NZ604306A (en) * | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| US9815831B2 (en) * | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
-
2011
- 2011-05-13 NZ NZ604306A patent/NZ604306A/en not_active IP Right Cessation
- 2011-05-13 CN CN201710716037.8A patent/CN107674073B/zh not_active Expired - Fee Related
- 2011-05-13 EP EP18192628.8A patent/EP3450432A1/en not_active Withdrawn
- 2011-05-13 EA EA201291098A patent/EA025281B9/ru unknown
- 2011-05-13 EP EP11730442.8A patent/EP2571878B1/en not_active Not-in-force
- 2011-05-13 AU AU2011254242A patent/AU2011254242B2/en not_active Ceased
- 2011-05-13 JP JP2013510708A patent/JP5960688B2/ja not_active Expired - Fee Related
- 2011-05-13 NZ NZ703111A patent/NZ703111A/en not_active IP Right Cessation
- 2011-05-13 CN CN201180032707.5A patent/CN103068824B/zh not_active Expired - Fee Related
- 2011-05-13 CA CA2798080A patent/CA2798080C/en not_active Expired - Fee Related
- 2011-05-13 EA EA201690998A patent/EA201690998A1/ru unknown
- 2011-05-13 CA CA3084173A patent/CA3084173A1/en not_active Abandoned
- 2011-05-13 KR KR1020127032963A patent/KR101871436B1/ko not_active Expired - Fee Related
- 2011-05-13 WO PCT/IB2011/052120 patent/WO2011145035A1/en not_active Ceased
- 2011-05-13 ES ES11730442T patent/ES2715611T3/es active Active
- 2011-05-13 DK DK11730442.8T patent/DK2571878T3/en active
- 2011-05-16 US US13/108,642 patent/US8481739B2/en not_active Expired - Fee Related
-
2012
- 2012-11-11 IL IL222977A patent/IL222977A/en active IP Right Grant
-
2013
- 2013-05-10 US US13/891,961 patent/US8912331B2/en not_active Expired - Fee Related
-
2014
- 2014-11-06 US US14/534,909 patent/US20150133449A1/en not_active Abandoned
-
2015
- 2015-06-11 IL IL239361A patent/IL239361B/en active IP Right Grant
-
2016
- 2016-01-29 AU AU2016200569A patent/AU2016200569B2/en not_active Ceased
- 2016-04-15 JP JP2016081792A patent/JP6286472B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-09 US US15/454,760 patent/US10087182B2/en not_active Expired - Fee Related
-
2018
- 2018-08-22 US US16/109,422 patent/US10590129B2/en not_active Expired - Fee Related